EP
CGON icon

Essential Partners’s CG Oncology CGON Stock Holding History

Essential Partners’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.25K Sell
88
-68
-44% -$4.45K ﹤0.01% 1436
2026
Q1 		$10.6K Hold
156
– – ﹤0.01% 1230
2025
Q4 		$6.48K Hold
156
– – ﹤0.01% 1322
2025
Q3 		$6.28K Hold
156
– – ﹤0.01% 1343
2025
Q2 		$4.06K Buy
+156
New +$3.76K ﹤0.01% 1113

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's CGON Position: Q2 2026 in Review

Essential Partners reduced its CG Oncology (CGON) stake by 44% in Q2 2026, selling an estimated $4.45K and leaving 88 shares worth $6.25K. The position accounts for ﹤0.01% of the portfolio, ranked #1436.

Essential Partners first reported a position in CGON in Q2 2025 and has held it in 5 quarters since. The position peaked at $10.6K in Q1 2026. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Essential Partners held 88 shares of CG Oncology worth $6.25K as of Q2 2026.
  • Essential Partners sold 68 CG Oncology shares in Q2 2026, an estimated $4.45K.
  • CG Oncology made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1436 holding.
  • Essential Partners first reported a position in CG Oncology in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's CG Oncology position peaked at $10.6K in Q1 2026.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.